MedTrace Logo

Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis

NCT02716103 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2021-09-10

No results posted yet for this study

Summary

In this study, the investigators seek to evaluate bone marrow and blood samples and treatment responses to see if Minimal Residual Disease (MRD) can be used as a predictive method of response to treatment in amyloidosis.

Conditions

  • Amyloidosis

Interventions

OTHER

blood collection

OTHER

bone marrow collection

Sponsors & Collaborators

  • Boston Medical Center

    lead OTHER

Principal Investigators

  • Shayna Sarosiek, MD · Boston Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-21
Primary Completion
2020-09-04
Completion
2020-09-04

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02716103 on ClinicalTrials.gov